Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30 weeks’ treatment with semaglutide

Abstract Background Individuals with schizophrenia suffer from reduced life expectancy, primarily due to obesity-related metabolic disorders and cardiovascular disease (CVD). The presence of cardiac autonomic neuropathy (CAN) may contribute to CVD, but CAN is reversible, and it may improve following...

全面介紹

書目詳細資料

Principais autores:	Ashok Ainkaran Ganeshalingam, Nicolai Gundtoft Uhrenholt, Sidse Arnfred, Peter Gæde, Andreas Kristian Pedersen, Niels Bilenberg, Jan Frystyk
格式:	Artigo
語言:	Inglês
出版:	BioMed Central 2026-01-01
叢編:	Cardiovascular Diabetology. Endocrinology Reports
主題:	Schizophrenia Prediabetes Prevention Cardiovascular autonomic neuropathy Antipsychotic treatment Obesity
在線閱讀:	https://doi.org/10.1186/s40842-025-00258-0
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!